Investor anticipation ahead of fresh trial results propelled Nektar Therapeutics (NASDAQ: NKTR) to notable market momentum on Monday. Following a 12.10% rise during the regular session, when the stock ended at $9.54, shares jumped 35.32% in after-hours trading to close at $12.91. The rise preceded a webcast and investor call to reveal top-line findings from a worldwide Phase 2b study.
Future Data Presentation Encourages Market Hope
Initial findings from the 16-week induction phase of the current REZOLVE-AD study will be the focus of the investor call and live webcast. In this study, individuals with moderate-to-severe atopic dermatitis are evaluated for the effectiveness of Nektar Therapeutics’ experimental treatment, rezpegaldesleukin, a regulatory T-cell (Treg) stimulator. Key findings will be detailed in a morning news release that will accompany the presentation. A webcast replay will be accessible on the company’s investor relations website for at least 30 days after the event.
Clinical Program Development Across Indications
With 396 patients enrolled in the REZOLVE-AD study, Nektar Therapeutics met its enrollment goal in January. The following month, NKTR also completed the enrollment of 84 patients with severe-to-very severe alopecia areata in the Phase 2b study, REZOLVE-AA.
Additionally, Nektar Therapeutics conducted a Phase 2 trial evaluating rezpegaldesleukin in around 70 people who had just been diagnosed with type 1 diabetes in collaboration with a leading diabetes research consortium TrialNet.
Regulatory Recognition and Global Scientific Opinions
Rezpegaldesleukin’s promise as a medicine was further supported in February when the U.S. Food and Drug Administration (FDA) granted it Fast Track designation. Nektar Therapeutics’ collaborative work was showcased at the 30th Annual Congress of the European Hematological Association (EHA) in Milan.
The presentation was developed in partnership with the Fred Hutchinson Cancer Center that highlighted the positive results that NKTR-255 and lisocabtagene maraleucel produced for patients with relapsed or refractory large B-cell lymphoma.
Because of its strong clinical pipeline and regulatory achievements, continue to bolster investor confidence, Nektar Therapeutics (NKTR) is positioned as a leading competitor in immune-modulating medications.
